Human papillomavirus vaccine: The beginning of the end for cervical cancer

Israel Medical Association Journal

Volumn 9, Issue 3, 2007, Pages 156-158

  Bornstein, Jacob ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Condylomata acuminata; Human papillomavirus; Vaccine

Indexed keywords

CAPSID PROTEIN; PLACEBO; VIRUS ANTIBODY; WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER MORTALITY; CARCINOGENESIS; CARCINOGENICITY; CLINICAL TRIAL; CONDYLOMA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; ISRAEL; MEDICAL RESEARCH; PROPHYLAXIS; QUALITY OF LIFE; SEXUAL MATURATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LIKE AGENT; WART VIRUS;

CLINICAL TRIALS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 33947491493     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Koutsky LA, Ault KA Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347: 1645-51.
2. Lowy DR, Frazer IH. Prophylactic human papillomavirus vaccines. Chapter 16. J Natl Cancer Inst 2003;31:111-16.
3. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
5. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27.
6. Munger K, Howley PM. Human papillomavirus immortalization and tansformation functions. Virus Res 2002;89:213-28.
7. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L2 virus-like particle vaccine In young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
8. Wright TC Jr, Cox JT, Massad LS et al. ASCCP-sponsored consensus conference. 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. JAMA 2002; 287:2120-9.
9. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-22.
10. Wideroff L, Schiffman M, Haderer P, et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles In a case-control study of cervical squamous intraepithelial lesions. J Infect Dis 1999;180:1424-8.
11. Mao C, Koutsky L, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27
12. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-65.
13. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
14. Munoz N. Efficacy of a quadrivalent HPV (types 6,11,16,18) L1 VLP vaccine against cervical intraepithelial neoplasia grades 1-3 and adenocarcinoma in situ: a combined analysis. Presented at EUROGIN, Paris, May 2006.
15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367(9518):1247-55
16. Harper DM for the FUTURE I Study Group. Oral presentation at: Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, December 2005
17. Koutsky L for the FUTURE II Study Group. Oral presentation at: Infectious Disease Society of America Annual Meeting; San Francisco, October 2005.
18. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005;191: S97-106.
19. Stein R. Cervical cancer vaccine gets infected with a social issue. Washington Post 2005, p. 3A.
20. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006;28:88-100.